Literature DB >> 33456581

Evodiamine inhibits both stem cell and non-stem-cell populations in human cancer cells by targeting heat shock protein 70.

Seung Yeob Hyun1, Huong Thuy Le1, Hye-Young Min1,2, Honglan Pei1, Yijae Lim2, Injae Song2, Yen T K Nguyen2, Suckchang Hong2, Byung Woo Han2, Ho-Young Lee1,2.   

Abstract

Rationale: Cancer stem cells (CSCs) are known to cause tumor recurrence and drug resistance. The heat shock protein (HSP) system plays a major role in preserving expression and function of numerous oncoproteins, including those involved in the CSC activities. We explored novel anticancer drugs, especially those targeting HSP components required for the functional role of CSCs.
Methods: Investigation of the role of the HSP system in CSCs and screening of a natural product chemical library were performed by utilizing cancer cell lines, primary cultures of patient-derived xenografts (PDXs), and their putative CSC subpopulations (i.e., those grown under sphere-forming conditions, stably transfected with reporter vectors carrying NANOG or POUSF1 promoters, or carrying high ALDH activity) in vitro and PDX and Kras G12D/+-driven tumor models in vivo. Regulation of the HSP system was investigated by immunoprecipitation, drug affinity responsive target stability assay, binding experiments using ATP-agarose beads and biotinylated drug, and docking analysis.
Results: The HSP system was activated in CSCs via transcriptional upregulation of the HSP system components, especially HSP70. Evodiamine (Evo) was identified to induce apoptosis in both CSC and bulk non-CSC populations in human lung, colon, and breast cancer cells and their sublines with chemoresistance. Evo administration decreased the multiplicity, volume, and load of lung tumors in Kras G12D/+ transgenic mice and the growth of cancer cell line- and PDX-derived tumors without detectable toxicity. Mechanistically, Evo disrupted the HSP system by binding the N-terminal ATP-binding pocket of HSP70 and causing its ubiquitin-mediated degradation. Conclusions: Our findings illustrate HSP70 as a potential target for eliminating CSCs and Evo as an effective HSP70-targeting anticancer drug eradicating both CSCs and non-CSCs with a minimal toxicity. © The author(s).

Entities:  

Keywords:  alkaloid; antitumor; cancer stem cells; evodiamine; heat shock protein 70

Year:  2021        PMID: 33456581      PMCID: PMC7806467          DOI: 10.7150/thno.49876

Source DB:  PubMed          Journal:  Theranostics        ISSN: 1838-7640            Impact factor:   11.556


  75 in total

Review 1.  Heat shock proteins--modulators of apoptosis in tumour cells.

Authors:  E M Creagh; D Sheehan; T G Cotter
Journal:  Leukemia       Date:  2000-07       Impact factor: 11.528

Review 2.  Ubiquitin and ubiquitin-like proteins in protein regulation.

Authors:  Joerg Herrmann; Lilach O Lerman; Amir Lerman
Journal:  Circ Res       Date:  2007-05-11       Impact factor: 17.367

3.  Recognizing and exploiting differences between RNAi and small-molecule inhibitors.

Authors:  William A Weiss; Stephen S Taylor; Kevan M Shokat
Journal:  Nat Chem Biol       Date:  2007-12       Impact factor: 15.040

4.  Features of free software packages in flow cytometry: a comparison between four non-commercial software sources.

Authors:  Fazel Sahraneshin Samani; Jodene K Moore; Pardis Khosravani; Marzieh Ebrahimi
Journal:  Cytotechnology       Date:  2013-07-10       Impact factor: 2.058

5.  ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays.

Authors:  Yifang Hu; Gordon K Smyth
Journal:  J Immunol Methods       Date:  2009-06-28       Impact factor: 2.303

Review 6.  Hsp90 and Hsp70 chaperones: Collaborators in protein remodeling.

Authors:  Olivier Genest; Sue Wickner; Shannon M Doyle
Journal:  J Biol Chem       Date:  2018-11-06       Impact factor: 5.157

7.  Cancer stem cells: the challenges ahead.

Authors:  Jan Paul Medema
Journal:  Nat Cell Biol       Date:  2013-04       Impact factor: 28.824

8.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

Review 9.  HSP70 and HSP90 in neurodegenerative diseases.

Authors:  Abha Gupta; Ankush Bansal; Kazue Hashimoto-Torii
Journal:  Neurosci Lett       Date:  2019-12-06       Impact factor: 3.046

Review 10.  Targeting Lung Cancer Stem Cells: Research and Clinical Impacts.

Authors:  Norashikin Zakaria; Nazilah Abdul Satar; Noor Hanis Abu Halim; Siti Hawa Ngalim; Narazah Mohd Yusoff; Juntang Lin; Badrul Hisham Yahaya
Journal:  Front Oncol       Date:  2017-05-05       Impact factor: 6.244

View more
  8 in total

Review 1.  Evodiamine as an anticancer agent: a comprehensive review on its therapeutic application, pharmacokinetic, toxicity, and metabolism in various cancers.

Authors:  Munmun Panda; Surya Kant Tripathi; Gokhan Zengin; Bijesh K Biswal
Journal:  Cell Biol Toxicol       Date:  2022-09-23       Impact factor: 6.819

2.  Targeting epidermal growth factor receptor in paclitaxel-resistant human breast and lung cancer cells with upregulated glucose-6-phosphate dehydrogenase.

Authors:  Hye-Young Min; Ho Jin Lee; Young-Ah Suh; Honglan Pei; Hyukjin Kwon; Hyun-Ji Jang; Hye Jeong Yun; Hyeong-Gon Moon; Ho-Young Lee
Journal:  Br J Cancer       Date:  2022-05-21       Impact factor: 9.075

3.  Antitumor Effects of Evodiamine in Mice Model Experiments: A Systematic Review and Meta-Analysis.

Authors:  Cong Yin; Jing Cheng; Hongbing Peng; Shijun Yuan; Keli Chen; Juan Li
Journal:  Front Oncol       Date:  2021-11-09       Impact factor: 6.244

4.  A novel C-terminal heat shock protein 90 inhibitor that overcomes STAT3-Wnt-β-catenin signaling-mediated drug resistance and adverse effects.

Authors:  Ho Jin Lee; Hye-Young Min; Young-Sik Yong; Jihyae Ann; Cong Truong Nguyen; Minh Thanh La; Seung Yeob Hyun; Huong Thuy Le; Hyewon Kim; Hyukjin Kwon; Gibeom Nam; Hyun-Ju Park; Jeewoo Lee; Ho-Young Lee
Journal:  Theranostics       Date:  2022-01-01       Impact factor: 11.600

5.  Ninjurin1 drives lung tumor formation and progression by potentiating Wnt/β-Catenin signaling through Frizzled2-LRP6 assembly.

Authors:  Seung Yeob Hyun; Hye-Young Min; Ho Jin Lee; Jaebeom Cho; Hye-Jin Boo; Myungkyung Noh; Hyun-Ji Jang; Hyo-Jong Lee; Choon-Sik Park; Jong-Sook Park; Young Kee Shin; Ho-Young Lee
Journal:  J Exp Clin Cancer Res       Date:  2022-04-08

Review 6.  Anoikis resistance in diffuse glioma: The potential therapeutic targets in the future.

Authors:  Zhengyang Zhu; Chaoyou Fang; Houshi Xu; Ling Yuan; Yichao Du; Yunjia Ni; Yuanzhi Xu; Anwen Shao; Anke Zhang; Meiqing Lou
Journal:  Front Oncol       Date:  2022-08-15       Impact factor: 5.738

7.  Targeting Triple Negative Breast Cancer Stem Cells by Heat Shock Protein 70 Inhibitors.

Authors:  Chia-Hung Tsai; Jing-Ru Weng; Hsiang-Wen Lin; Meng-Tien Lu; Yu-Chi Liu; Po-Chen Chu
Journal:  Cancers (Basel)       Date:  2022-10-07       Impact factor: 6.575

Review 8.  HSP70s in Breast Cancer: Promoters of Tumorigenesis and Potential Targets/Tools for Therapy.

Authors:  Alexander E Kabakov; Vladimir L Gabai
Journal:  Cells       Date:  2021-12-07       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.